Mortality and Additional Treatment Rates in Pathologically High‐Risk Prostate Cancer With Prostate‐Specific Antigen Persistence at Robot‐Assisted Radical Prostatectomy: Long‐Term Report From Single Tertiary Referral Center

Patients with pathologically high-risk PCa and PSA persistence after RALP, despite being at greater hazard of AT (HT and/or RT), did not have less favorable cancer control outcomes at 10 years than their counterparts with undetectable PSA levels. Our report provides the longest follow-up after RALP for this subset of patients, making it a valuable resource for counseling patients on the long-term oncologic outcomes of this procedure and postoperative adjuvant/salvage therapies.

Authors

Institutions

Publication Details

Journal
The Prostate
Published
2025-08-10
DOI
https://doi.org/10.1002/pros.70031
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mortality and Additional Treatment Rates in Pathologically High‐Risk Prostate Cancer With Prostate‐Specific Antigen Persistence at Robot‐Assisted Radical Prostatectomy: Long‐Term Report From Single Tertiary Referral Center

Gabriele Sorce, Akshay Sood, Alessandro Bertini, Giovanni Lughezzani et al.
The Prostate
Prostate Cancer Diagnosis and Treatment
article

Mortality and Additional Treatment Rates in Pathologically High‐Risk Prostate Cancer With Prostate‐Specific Antigen Persistence at Robot‐Assisted Radical Prostatectomy: Long‐Term Report From Single Tertiary Referral Center

Gabriele Sorce, Akshay Sood, Alessandro Bertini, Giovanni Lughezzani, Nicolò Maria Buffi, Andrea Salonia, Annamaria Perri, Firas Abdollah, Francesco Montorsi, Silvia Viganò, Alex Stephens, Alessio Finocchiaro, Mani Menon, Vincenzo Ficarra, Craig A. Rogers, Alberto Briganti
article en

Abstract

Patients with pathologically high-risk PCa and PSA persistence after RALP, despite being at greater hazard of AT (HT and/or RT), did not have less favorable cancer control outcomes at 10 years than their counterparts with undetectable PSA levels. Our report provides the longest follow-up after RALP for this subset of patients, making it a valuable resource for counseling patients on the long-term oncologic outcomes of this procedure and postoperative adjuvant/salvage therapies.

The ProstateVol. 85(16)
University of Messina (IT), Humanitas University (IT), Henry Ford Health System (US), Vita-Salute San Raffaele University (IT), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), The Ohio State University Wexner Medical Center (US), IRCCS Ospedale San Raffaele (IT), IRCCS Humanitas Research Hospital (IT)
Good health and well-being
Openalex Percentile: Top 69%
Prostate Cancer Diagnosis and Treatment
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.